---
title: 'Industry Daily Summary: What Happened on November 16, 2026'
headline: J&J agrees to buy Ollin for up to $3.3 billion
description: Lilly agreed to buy Calytrix for up to $1.5 billion. Novartis and Sanofi
  also signed research deals.
url: https://thebench.bio/news/industry/2026-11-16
topic: industry
date: '2026-11-16'
covers:
- '2026-11-16'
date_published: '2026-11-16T12:03:31Z'
date_modified: '2026-11-17T00:05:09Z'
tags:
- Industry
- Funding
sources: 8
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 16, 2026

**J&J agrees to buy Ollin for up to $3.3 billion**

Lilly agreed to buy Calytrix for up to $1.5 billion. Novartis and Sanofi also signed research deals.

## Today in brief

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, plus up to $1.125 billion in milestones. [1] [2] The deal brings OLN324, an antibody in Phase 3 development for eye disease, and up to $750 million in development funding from Blackstone Life Sciences. [1] [2]

Lilly will acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody program for rare blood disorders. [3] [4] Novartis licensed OBI Pharma’s platform for cancer antibody-drug conjugates, and Sanofi struck a research and licensing agreement with Seawolf Therapeutics. [3]

## J&J will pay $2.2 billion upfront for Ollin

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with up to $1.125 billion more tied to regulatory and commercial milestones. [1] [2] Ollin’s lead program, OLN324, is a bispecific antibody in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. [1] [2]

OLN324 targets VEGF and Ang2, pathways involved in retinal disease that Roche’s Vabysmo also targets. [1] [2] Ollin said a Phase 1b head-to-head study found greater structural changes and numerically greater vision improvement with OLN324 than with Vabysmo. [2] In another reported comparison, 82% of participants on a 4 mg dose went 12 weeks without retreatment, versus 81% on faricimab. [3]

J&J will lead the pivotal trials, while Blackstone Life Sciences agreed to fund up to $750 million for late-stage development. [2] [4] The acquisition also includes OLN102, an investigational antibody for thyroid eye disorder. [2] The companies expect the deal to close before the end of 2026, subject to regulatory approvals and customary conditions. [3] [4]

## Lilly adds Calytrix’s preclinical blood-disorder program

Lilly agreed to buy Calytrix Bio in a cash deal worth up to $1.5 billion. The total includes an upfront payment whose amount wasn’t disclosed, plus clinical and regulatory milestones. [3] [4] Calytrix’s lead program is a preclinical antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. [3] [4]

Calytrix says the target could let the antibody remove disease-driving cells while preserving healthy blood-cell production. [3] One account counted the deal as Lilly’s 15th announced acquisition of 2026. Another counted 14. [3] [5]

## Novartis and Sanofi sign research partnerships

Novartis signed a collaboration and license agreement with OBI Pharma to develop next-generation antibody-drug conjugates using OBI’s platform. [3] OBI will receive $30 million upfront, with possible milestone payments and tiered royalties. Novartis gets worldwide rights to selected payload classes and an option to add others. [3]

Seawolf Therapeutics raised $100 million in seed and Series A funding and signed a research collaboration and exclusive license agreement with Sanofi. [3] The agreement covers bleeding disorders and undisclosed indications, with potential milestone payments of up to $1.2 billion plus tiered royalties. [3]

Seawolf says its DNA-delivery platform could produce proteins longer than RNA-based lipid nanoparticles and allow redosing, unlike viral gene therapies. [3]

## Also worth knowing

- Medtronic plans to buy Contego Medical for $380 million to expand its offerings for carotid artery and peripheral vascular disease. [6]
- Revolution Medicines CEO Mark Goldsmith said the US launch of Rasonque is advancing quickly but is complicated by expanded access, which provided the drug to more than 2,000 patients. [7]
- TRIMTECH and Biogen signed a protein-degrader research and licensing-option deal worth up to $411 million plus royalties, including up to $32 million in upfront and research payments. [8]
- AmyriAD Therapeutics acquired worldwide rights to AD04, a mild Alzheimer’s disease program described as ready for Phase 2b development. [4]

## The day in numbers

- **$3.3 billion**: Maximum stated value of J&J’s Ollin acquisition, including upfront and milestone payments. [1]
- **$750 million**: Maximum Blackstone Life Sciences funding for OLN324’s late-stage development. [2] [4]
- **$1.5 billion**: Maximum cash consideration in Lilly’s acquisition of Calytrix. [3] [4]

## Also published

- [Executive Conversations: What Sets Strategic Trade Teams Apart?](<https://www.pharmaceuticalcommerce.com/view/executive-conversations-what-sets-strategic-trade-teams-apart>), Pharmaceutical Commerce
- [The Adaptive HCP Engagement Playbook](<https://www.fiercebiotech.com/resource/adaptive-hcp-engagement-playbook>), Fierce Biotech
- [J&J bets $2.2B on Ollin’s vision loss drug](<https://www.biopharmadive.com/news/Johnson-johnson-ollin-acquire-ophthalmology-vegf-ang2-drugs/874728/>), BioPharma Dive
- [STAT+: Biotech’s rebound isn’t lifting all boats equally](<https://www.statnews.com/2026/11/16/biotech-news-rebound-isnt-lifting-all-boats-equally/?utm_campaign=rss>), STAT Biotech
- [J&J cuts $3.3bn deal to buy eye drug developer Ollin](<https://pharmaphorum.com/news/jj-cuts-33bn-deal-buy-eye-drug-developer-ollin>), pharmaphorum
- [China’s pharma industry wants to go global. The US could get in its way.](<https://www.pharmavoice.com/news/china-pharma-global-expansion-us-commercialization/874673/>), PharmaVoice
- [Lilly strikes again, buying Calytrix in $1.5bn deal](<https://pharmaphorum.com/news/lilly-strikes-again-buying-calytrix-15bn-deal>), pharmaphorum
- [An AAPS PharmSci 360 overview: Making better decisions faster, earlier, with fewer resources](<https://pharmaphorum.com/rd/aaps-pharmsci-360-overview-making-better-decisions-faster-earlier-fewer-resources>), pharmaphorum
- [Q3 2026 Earnings Review](<https://mattbiotech.substack.com/p/q3-2026-earnings-review>), Matt Gamber
- [China overtakes Europe in healthcare investing sentiment](<https://pharmaphorum.com/news/china-overtakes-europe-healthcare-investing-sentiment>), pharmaphorum
- [BeOne, Hengrui top list of China’s most powerful drugmakers](<https://www.statnews.com/2026/11/16/beone-hengrui-top-list-of-chinas-most-powerful-drugmakers/?utm_campaign=rss>), STAT Biotech
- [Notable TechBio startups and companies operating in India 🇮🇳 (II)](<https://marinatalamanou.substack.com/p/notable-techbio-startups-and-companies-315>), MetaphysicalCells
- [From Hong Kong to Düsseldorf: HKSTP Makes MEDICA Debut with Breakthrough MedTech Ventures](<https://www.clinicaltrialsarena.com/sponsored/from-hong-kong-to-dusseldorf-hkstp-makes-medica-debut-with-breakthrough-medtech-ventures/>), Clinical Trials Arena
- [ASHG Notes: TTP plc's Lysate-to-Library Prototype](<https://omicsomics.blogspot.com/feeds/5795928413584163401/comments/default>), Omics! Omics!

## Sources

1. [J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences](<https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>), Pharmaceutical Technology, 2026-11-16
2. [J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding](<https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>), MedCity News, 2026-11-16
3. [Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts](<https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts>), BioPharm International, 2026-11-16
4. [M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD Therpaeutics Acquires AD04 Alzheimers Program, Sanofi Enters Collaboration with Seawolf Therapeutics](<https://www.pharmexec.com/view/johnson-acquires-ollin-biosciences-eli-lilly-calytrix-bio-amyriad-therpaeutics-ad04-alzheimers-sanofi-collaboration-seawolf-therapeutics>), Pharmaceutical Executive, 2026-11-16
5. [Lilly adds to buyout streak with $1.5B purchase of startup Calytrix](<https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/>), BioPharma Dive, 2026-11-16
6. [Medtronic to buy Contego Medical for $380M](<https://www.medtechdive.com/news/medtronic-to-buy-contego-medical-for-380m/874754/>), MedTech Dive, 2026-11-16
7. [RevMed CEO on tackling “complex” launch for wonder pancreatic drug](<https://www.pharmaceutical-technology.com/news/revmed-ceo-on-tackling-complex-launch-for-pancreatic-drug/>), Pharmaceutical Technology, 2026-11-16
8. [TRIMTECH lands $411M Biogen deal for neurodegeneration protein degraders](<https://european-biotechnology.com/latest-news/trimtech-lands-411m-biogen-deal-for-neurodegeneration-protein-degraders/>), European Biotechnology, 2026-11-16

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>
[2]: <https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>
[3]: <https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts>
[4]: <https://www.pharmexec.com/view/johnson-acquires-ollin-biosciences-eli-lilly-calytrix-bio-amyriad-therpaeutics-ad04-alzheimers-sanofi-collaboration-seawolf-therapeutics>
[5]: <https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/>
[6]: <https://www.medtechdive.com/news/medtronic-to-buy-contego-medical-for-380m/874754/>
[7]: <https://www.pharmaceutical-technology.com/news/revmed-ceo-on-tackling-complex-launch-for-pancreatic-drug/>
[8]: <https://european-biotechnology.com/latest-news/trimtech-lands-411m-biogen-deal-for-neurodegeneration-protein-degraders/>
